Here we demonstrate that EGFR-activated ERK2 binds directly to PKM2 Ile 429/Leu 431 through the ERK2 docking groove and phosphorylates PKM2 at Ser 37, but does not phosphorylate PKM1. Phosphorylated PKM2 Ser 37 recruits PIN1 for cis -trans isomerization of PKM2, which promotes PKM2 binding to importin α5 and translocating to the nucleus. Nuclear PKM2 acts as a coactivator of β-catenin to induce c-Myc expression, resulting in the upregulation of GLUT1, LDHA and, in a positive feedback loop, PTB-dependent PKM2 expression. Replacement of wild-type PKM2 with a nuclear translocation-deficient mutant (S37A) blocks the EGFR-promoted Warburg effect and brain tumour development in mice. In addition, levels of PKM2 Ser 37 phosphorylation correlate with EGFR and ERK1/2 activity in human glioblastoma specimens. Our findings highlight the importance of nuclear functions of PKM2 in the Warburg effect and tumorigenesis.
PKM2 to phosphorylated β-catenin Tyr 333 is required for epidermal growth factor receptor (EGFR)-induced β-catenin transactivation and cell cycle progression 10, 13 . Importantly, PKM2 functions as a protein kinase, phosphorylating histone H3 Thr 11 and leading to H3 Lys 9 acetylation and transcription of genes, including CCND1 (coding for cyclin D1) and MYC (ref. 14) .
In this report, we demonstrate that extracellular signal-regulated kinase (ERK)-dependent phosphorylation and nuclear translocation of PKM2 is required for the autoregulation of PKM2 expression and PKM2-dependent expression of glycolytic genes, which are essential for the EGFR-promoted Warburg effect and tumorigenesis.
RESULTS

ERK is required for PKM2 nuclear translocation
To understand the mechanism of PKM2 accumulation in the nucleus, we carried out immunofluorescence analysis and showed that PKM2, a primarily cytosolic protein, translocated to the nucleus following EGF stimulation in U251 human glioblastoma multiforme (GBM) cells ( Supplementary Fig. S1a , left panel). This result is in line with our findings that EGFR activation by EGF Immunoblotting and immunoprecipitation analyses were carried out with antibodies against the indicated proteins. (a) Nuclear fractions were prepared from U87/EGFR cells pretreated with LY290042 (30 µM), SU6656 (4 µM), SP600125 (25 µM) and U0126 (20 µM) for 30 min before treating with EGF (100 ng ml −1 ) for 6 h. Nuclear proliferating-cell nuclear antigen (PCNA) and cytoplasmic tubulin were used as controls. WB, Western blot. (b) U87/EGFR cells were pretreated with or without U0126 (20 µM) for 30 min before treating with EGF (100 ng ml −1 ) for 6 h. Immunofluorescence analyses were carried out with antibodies against the indicated proteins. Nuclei were stained with Hoechst 33342 (blue). (c) U251 cells were stably transfected with a vector with or without expressing Flag-ERK2 K52R (left panel) or transiently transfected with vectors expressing MEK1 Q56P and indicated Flag-tagged ERK2 proteins (right panel). The cells were treated with or without EGF (100 ng ml −1 ) for 6 h, and the total cell lysates and nuclear fractions were prepared. WT, wild type. (d) Flag-PKM2 or Flag-PKM1 was immunoprecipitated (IP) with an anti-Flag antibody from U87/EGFR cells treated with or without EGF (100 ng ml −1 ) for 30 min. (e) Bacterially purified GST-ERK2 immobilized on glutathione agarose beads was mixed with or without purified His-PKM2. GST pulldown analyses were carried out. 10% of total His-PKM2 was used as an input. (f) U87/EGFR cells transfected with vectors expressing the indicated Flag-tagged ERK proteins were treated with or without EGF (100 ng ml −1 ) for 30 min. (g) U87/EGFR cells expressing the indicated Flag-PKM2 proteins were treated with or without EGF (100 ng ml −1 ) for 30 min. Uncropped images of blots/gels are shown in Supplementary Fig. S8 .
or by expression of the constitutively activated EGFR variant III (EGFRvIII) mutant promotes nuclear translocation of PKM2 (ref. 10) . In contrast, Flag-PKM1 did not show subcellular redistribution following EGF stimulation ( Supplementary Fig. S1a , right panel). Treatment with EGFR inhibitor AG1478, which blocked EGF-induced phosphorylation of EGFR and ERK1/2, abrogated EGF-induced nuclear accumulation of PKM2 ( Supplementary Fig. S1b ). Compared with the amount of cytosolic PKM2, nuclear PKM2 is a small portion ( Supplementary Fig. S1c ), which may account for the lack of reduction of cytoplasmic PKM2 expression following EGF treatment.
Pretreatment of U87/EGFR (Fig. 1a ) and U251 cells ( Supplementary  Fig. S1d ) with the phosphoinositide 3-kinase inhibitor LY290042, Src inhibitor SU6656, JNK inhibitor SP600125 and MAP-kinase kinase (MEK)/ERK inhibitor U0126 blocked EGF-induced phosphorylation of AKT, c-Src, c-Jun and ERK1/2, respectively ( Supplementary Fig. S1e ). Immunoblotting analyses showed that only inhibition of MEK/ERK abrogated EGF-induced nuclear translocation of PKM2 (Fig. 1a and Supplementary Fig. S1d ). These results were further supported by immunofluorescence analyses (Fig. 1b) . In addition, expression of the Flag-ERK2 K52R kinase-dead mutant blocked EGF-induced nuclear accumulation of PKM2 (Fig. 1c, left panel) . Co-expression of the constitutively active MEK1 Q56P mutant with Flag-tagged wild-type ERK2 or ERK2 K52R in U251 cells (Fig. 1c, right panel) showed that expression of wild-type ERK2, but not ERK2 K52R, induced nuclear translocation of PKM2. These results indicate that ERK activation is required for EGF-induced nuclear translocation of PKM2.
To further determine the relationship between ERK1/2 and PKM2, we carried out co-immunoprecipitation assays and revealed that EGF treatment resulted in ERK1/2 binding to Flag-PKM2 but not Flag-PKM1 (Fig. 1d ). An in vitro glutathione S-transferase (GST) pulldown assay with mixed purified GST-ERK2 and His-PKM2 showed that these two proteins interacted directly (Fig. 1e) . Mitogenactivated protein kinases bind to their substrates through a docking groove consisting of an acidic common docking domain and glutamic acid-aspartic acid pockets 15 . Immunoblotting of the immunoprecipitated Flag-ERK2 proteins with an anti-PKM2 antibody showed that mutation of either the ERK2 common docking domain (D316/319N) or the glutamic acid-aspartic acid pocket (T157/158E) reduced binding to endogenous PKM2, as compared with the wild-type ERK2 control. Combined mutations at both the common docking domain and glutamic acid-aspartic acid pocket (T/E-D/N) abrogated the binding of ERK2 to PKM2 entirely (Fig. 1f) , indicating that ERK2 binds to PKM2 through its docking groove.
ERK substrates often have a docking domain, which is characterized by a cluster of basic residues followed by an LXL motif (L represents leucine, but can also be isoleucine or valine; X represents any amino acid) 15 . Analysis of the PKM2 amino acid sequence with the Scansite program identified the putative ERK-binding sequence 422-KCCSGAIIVLTKSGR-436 in the region spanning amino acids 380-434, which contains LXL motifs at Ile 428/Val 430 and Ile 429/Leu 431. This series of amino acids is encoded by the PKM2-specific exon 10 and is thus unique to PKM2. Immunoblotting of the immunoprecipitated Flag-PKM2 proteins with an anti-ERK1/2 antibody showed that a PKM2 I429R/L431R mutant, but not a PKM2 I428R/V430A mutant, markedly reduced its binding to ERK1/2 (Fig. 1g) . These results indicate that the ERK2 docking groove binds to a docking domain in PKM2 at Ile 429/Leu 431.
ERK2 phosphorylates PKM2 Ser 37
An in vitro kinase assay mixing purified PKM2 with active ERK2 showed that ERK2 phosphorylated PKM2 (Fig. 2a) . Sequence analysis of PKM2 revealed that it contains an ERK consensus phosphorylation motif (serine-proline 15 ) at the Ser 37/Pro 38 residues. The S37A mutation completely abrogated the ERK2-dependent phosphorylation of PKM2 in vitro; this finding was further validated by a specific phospho-PKM2 Ser 37 antibody (Fig. 2a) .
Because PKM1 and PKM2 share the identical amino-terminal amino acid sequence (including Ser 37), we tested whether ERK2-mediated phosphorylation of Ser 37 is restricted to PKM2. Immunoblotting of the immunoprecipitated Flag-tagged PKM1 or PKM2 with the anti-phospho-PKM2 Ser 37 antibody showed that EGF treatment resulted in phosphorylation of wild-type PKM2 (Fig. 2b , left panel) but not PKM1 (Fig. 2b, right panel) or the PKM2 S37A mutant. Consistently, pretreatment with U0126 blocked EGF-induced Ser 37 phosphorylation and nuclear translocation of PKM2 (Fig. 2b , left panel; Supplementary Fig. S2a ). In addition, expression of constitutively active MEK1 Q56P with wild-type ERK2, but not with the ERK2 K52R mutant, induced PKM2 Ser 37 phosphorylation (Fig. 2c) . These results indicate that ERK2 specifically phosphorylates PKM2 but not PKM1, consistent with the presence of the docking domain in PKM2 (but not in PKM1) that enables unique ERK1/2 binding (Fig. 1d,g ).
Expression of Flag-tagged wild-type PKM2, the PKM2 S37A mutant or a phosphorylation-mimic PKM2 S37D mutant in U87/EGFR cells ( Fig. 2d) showed that the Flag-PKM2 S37A mutant was resistant to EGF-induced nuclear translocation, as determined by immunoblotting analyses (Fig. 2e, top Fig. 2b ). In contrast, the phosphorylation-mimic PKM2 S37D mutant had a higher level of nuclear accumulation in the absence of EGF treatment than did wild-type PKM2 or the S37A mutant (Fig. 2e , bottom panel, and Fig. 2f, right panel) . These results indicate that PKM2 phosphorylation at Ser 37 is required for nuclear translocation of PKM2.
PKM2 Ser 37 phosphorylation recruits PIN1
The peptidyl-proline isomerase protein interacting with never in mitosis A 1 (PIN1) recognizes phosphorylated pS/TP-peptide sequences and catalyses their cis-trans isomerization 16, 17 . EGF treatment induced a strong binding of endogenous PKM2 to His-PIN1 immobilized on nickel agarose beads (Fig. 3a) , whereas this binding was abrogated by pretreatment of cells with U0126 (Fig. 3a) or S37A mutation of PKM2 (Fig. 3b) . In addition, a His-PIN1 WW domain mutant, which prevents the binding of PIN1 to a pS/TP substrate 17 , failed to bind to endogenous PKM2 in U87/EGFR cells on EGF treatment (Fig. 3c) . These results indicate that the PIN1 WW domain binds to the ERK1/2-phosphorylated Ser 37 of PKM2.
To determine whether ERK1/2-dependent PKM2 phosphorylation is sufficient for PIN1 binding to PKM2, we mixed His-PKM2 with wild-type GST-PIN1 or a GST-PIN1 WW domain mutant in the presence or absence of active ERK2. As shown in Fig. 3d (left panel), phosphorylated PKM2, but not its nonphosphorylated counterpart, bound to wild-type PIN1, but not the PIN1 WW domain mutant. In addition, the purified phosphorylation-mimic His-PKM2 S37D mutant, but not His-PKM2 S37A, was able to interact with GST-PIN1 in the absence of ERK2 (Fig. 3d, right panel) . These in vitro results were validated by a co-immunoprecipitation assay showing that EGF stimulation greatly increased the binding of endogenous PIN1 to endogenous PKM2, which was blocked by U0126 pretreatment (Fig. 3e,  left panel) . In contrast to wild-type Flag-PKM2, the Flag-PKM2 S37D mutant was co-immunoprecipitated with PIN1 in the absence of EGF To further examine whether the phosphorylated Ser 37/Pro 38 motif of PKM2 is a PIN1 substrate, we synthesized oligopeptides of PKM2 containing phosphorylated or nonphosphorylated Ser 37/Pro 38. As demonstrated in Fig. 3f , GST-wild-type PIN1 isomerized the phosphorylated Ser 37/Pro 38 peptide much more efficiently than did a catalytically inactive GST-PIN1 C113A mutant (left panel), whereas wild-type PIN1 failed to isomerize the nonphosphorylated counterpart (right panel). These results suggest that PIN1 specifically isomerizes the phosphorylated Ser 37/Pro 38 within PKM2.
To determine the role of PIN1 in nuclear translocation of PKM2, we used EGF to treat PIN1 +/+ , PIN1 −/− or PIN1 −/− mouse embryonic fibroblasts with reconstituted expression of wild-type PIN1 or a PIN1 C113A mutant (Fig. 3g , left panel). PIN1 deficiency completely blocked EGF-induced nuclear translocation of human Flag-PKM2, whereas this block was rescued by re-expression of wild-type PIN1 but not by expression of the PIN1 C113A mutant (Fig. 3g, right panel) . These results indicate that the catalytic activity of PIN1 is required for EGF-induced nuclear translocation of PKM2. Furthermore, the nuclear translocation of the phosphorylation-mimic Flag-PKM2 S37D mutant ( Fig. 2e ) was inhibited by PIN1 deficiency (Fig. 3h) , indicating that phosphorylation of PKM2 by itself is not sufficient for PKM2 nuclear translocation, and further supporting a role for PIN1 in EGF-induced nuclear translocation of PKM2.
PIN1 regulates binding of PKM2 to importin α5
PIN1 contains a nuclear localization signal (NLS; ref. 18). We next tested whether PKM2 translocates to the nucleus with PIN1 in a PIN1 NLS-dependent manner. A PIN1 NLS (L60/61A) mutant, which was expressed in PIN1 −/− cells, failed to accumulate in the nucleus ( Supplementary Fig. S2c ). However, expression of this PIN1 mutant, whose catalytic activity was intact ( Supplementary Fig. S2d ), still permitted EGF-induced nuclear translocation of Flag-PKM2 ( Supplementary Fig. S2e ). These results indicate that the nuclear translocation of PKM2 is not mediated by the PIN1 NLS and suggest that these two proteins translocate to the nucleus separately. Furthermore, depletion of HIF-1α, which is a PKM2-associated protein 11 , did not affect the EGF-induced nuclear translocation of PKM2 and β-catenin Tyr 333 phosphorylation (which is required for β-catenin transactivation 10 ; Supplementary Fig. S2f ), suggesting separate nuclear translocation processes for these two proteins and β-catenin regulation independently of HIF-1α.
To test whether PKM2 contains a sterically inaccessible NLS that is exposed for importin binding after PIN1-mediated cis-trans isomerization, we mutated the Arg 399/400 and Arg 443/445/447 residues in the putative NLS sequences of the carboxy-domain (amino acids 393-531) encoded by PKM2-specific exon 10 (ref. 19 ) into alanine. Cell fractionation (Fig. 4a) and immunofluorescence (Fig. 4b) analyses showed that Flag-PKM2 R399/400A, unlike the R443/445/447A mutant or wild-type PKM2, was unable to translocate into the nucleus on EGF treatment. These results indicate that the NLS containing Arg 399/400 in PKM2, but not in PKM1, is essential for EGF-induced nuclear translocation of PKM2.
Importin α functions as an adaptor and links NLS-containing proteins to importin β, which then docks the ternary complex at the were treated with or without EGF (100 ng ml −1 ) for 30 min. The cell lysate was mixed with purified GST-importin α5 for a GST pulldown assay.
(e) U87/EGFR cells with or without depletion of importin α5 were treated with or without EGF (100 ng ml −1 ) for 6 h. The cytosolic and nuclear fractions were prepared. (f) Purified His-PKM2 S37D on nickel agarose beads was mixed with purified GST-importin α5 in the presence or absence of purified wild-type His-PIN1 or His-PIN1 C113A. A GST pulldown assay was carried out. Uncropped images of blots/gels are shown in Supplementary Fig. S8 .
nuclear-pore complex to facilitate the translocation of these proteins across the nuclear envelope. Six importin α family members (α1, α3, α4, α5, α6 and α7) have been identified in humans 20 . Figure 4c shows that EGF treatment resulted in endogenous PKM2 binding to importin α5, but not to α1, α3, α4 or α5 family members. In addition, purified GST-importin α5 was able to pull down wild-type Flag-PKM2, but not Flag-PKM2 R399/400A, from EGF-treated U87/EGFR cells (Fig. 4d) . Furthermore, depletion of importin α5 with KPNA1 (coding for importin α5) short hairpin RNA (shRNA; Fig. 4e ) largely blocked EGFinduced nuclear translocation of PKM2 and resulted in accumulated phosphorylated PKM2 Ser 37 in the cytosol (Fig. 4e) .
To determine whether PIN1 plays a role in the binding of PKM2 to importin α5, we mixed purified phosphorylation-mimic His-PKM2 S37D and GST-importin α5 in the presence or absence of wild-type His-PIN1 or the His-PIN1 C113A mutant. As shown in Fig. 4f , PKM2 S37D alone did not bind to importin α5. However, inclusion of wild-type PIN1, but not of the inactive PIN1 C113A mutant, enabled PKM2 S37D to interact with importin α5. These results strongly suggest that phosphorylation of PKM2 at Ser 37, which by itself is not sufficient for PKM2 nuclear translocation (Fig. 3h) , leads to cis-trans isomerization of PKM2 by PIN1 to expose intermolecularly or intramolecularly masked Arg 399/400 of the PKM2 NLS for binding to importin α5. In combination with our finding that the recruitment of PIN1 to PKM2 is mediated by both the binding of the ERK2 docking groove to the PKM2-specific exon 10-encoded Ile 429/Leu 431 region and the phosphorylation of PKM2 at Ser 37, these results highlight the significance of precise and sequential post-translational modifications of PKM2 and its interactions with ERK1/2, PIN1 and importin α5 in its nuclear translocation.
Nuclear PKM2 regulates glycolytic gene expression
Previously, we demonstrated that nuclear PKM2 interacts with phosphorylated β-catenin Tyr 333 for β-catenin transactivation 10 . TOPflash TCF/LEF-1 luciferase reporter analyses showed that PKM2 depletion significantly inhibited EGF-induced β-catenin transactivation, which was largely rescued by reconstituted expression of RNAi-resistant wild-type rPKM2 but not those of rPKM2 S37A (Fig. 5a) , wild-type Flag-PKM1 or Flag-PKM1 S37A ( Supplementary  Fig. S3a ). In addition, chromatin immunoprecipitation (ChIP) with an anti-β-catenin antibody showed that EGFR activation resulted in the binding of β-catenin to the MYC promoter, which was inhibited by PKM2 depletion (Fig. 5b and Supplementary Fig. S3b) . Notably, this inhibition was abrogated by expression of wild-type rPKM2 but not that of rPKM2 S37A. In addition, PIN1 depletion by PIN1 shRNA also blocked EGF-induced β-catenin transactivation (Fig. 5c) . These results indicate that PIN1-dependent nuclear translocation of PKM2 plays a critical role in EGF-induced β-catenin transactivation.
c-Myc expression is known to be upregulated by PKM2-dependent β-catenin transactivation 14, 21 . c-Myc transcriptionally induces expression of glucose transporter 1 (GLUT1) and lactate dehydrogenase A (LDHA; refs 22,23) and upregulates PTB expression, thereby regulating PKM pre-mRNA splicing for generation of PKM2 mRNA (refs 6,7). We next examined whether nuclear translocation of PKM2 plays a role in c-Myc-dependent expression of downstream genes. As shown in Fig. 5d , PKM2 depletion blocked EGF-enhanced expression of c-Myc, PTB, GLUT1 and LDHA, which was rescued by reconstituted expression of wild-type rPKM2 but not those of rPKM2 S37A, wild-type Flag-PKM1 or Flag-PKM1 S37A (Supplementary Fig. S3c ). Of note, EGF treatment resulted in PKM2 upregulation, which is in agreement with the enhanced expression of PTB by EGF (Fig. 5e) . Expression of Flag-PKM2 S37A or R399/400A blocked EGF-induced upregulation of c-Myc, PTB, PKM2, GLUT1 and LDHA.
In line with these findings, c-Myc depletion blocked EGF-induced upregulation of PTB, PKM2, GLUT1 and LDHA (Fig. 5f ). These results indicate that nuclear translocation of PKM2 plays a pivotal role in EGF-induced β-catenin transactivation, which results in a subsequent upregulation of PTB, PKM2, LDHA and GLUT1 expression in a c-Myc-dependent manner.
Nuclear PKM2 is required for the Warburg effect GLUT1 and LDHA are required for glucose uptake and the conversion of pyruvate to lactate, respectively 8 . To investigate the role of nuclear translocation of PKM2 in EGFR-regulated tumour cell glycolysis, we depleted PKM2 with PKM2 shRNA in EGFRvIII-expressing U87 cells and reconstituted these cells with wild-type rPKM2, rPKM2 S37A (Fig. 6a) and wild-type Flag-PKM1 (Supplementary Fig. S4a ). PKM2 depletion significantly reduced glucose consumption and lactate production (Fig. 6b ), which were rescued by reconstituted expression of wild-type PKM2, but not that of PKM2 S37A (Fig. 6b) or wild-type Flag-PKM1 (Supplementary Fig. S4b ). Because the S37A mutation did not affect PKM2 kinase activity ( Supplementary Fig. S4c ), these results indicate that nuclear translocation of PKM2, which results in upregulation of PKM2 itself, GLUT1 and LDHA, is essential for the EGFR-induced Warburg effect. These findings were further supported by results showing that depletion of GLUT1, LDHA and PTB greatly reduced glucose consumption and lactate production ( Supplementary Fig. S4d-f) . Acting similarly to EGF, platelet-derived growth factor (PDGF) induced nuclear translocation of PKM2, which was blocked by pretreatment with U0126 ( Supplementary Fig. S5a ). In addition, U0126 treatment blocked PDGF-induced glucose uptake and lactate production ( Supplementary Fig. S5b ), suggesting that activation of both EGFR and PDGFR promotes the Warburg effect mediated by ERK1/2-dependent nuclear translocation of PKM2.
To investigate the role of nuclear translocation of PKM2 in brain tumorigenesis, we intracranially injected U87/EGFRvIII, U87/EGFRvIII-PKM2 shRNA and U87/EGFRvIII-PKM2 shRNA cells with reconstituted expression of wild-type rPKM2, rPKM2 S37A, wild-type Flag-PKM1 and Flag-PKM1 S37A into athymic nude mice. Depletion of PKM2 abrogated the growth of brain tumours, which was rescued by reconstituted expression of wild-type rPKM2, but not that of rPKM2 S37A (Fig. 6c and Supplementary Fig. S6a ) or wild-type Flag-PKM1 (Supplementary Fig. S6b) . Similar results on PKM2-dependent Warburg effect and tumorigenesis were also obtained using human primary GSC11 GBM cells ( Supplementary  Fig. S7a-c) . In addition, depletion of GLUT1, LDHA and PTB inhibited EGFRvIII-induced brain tumour growth ( Supplementary  Fig. S7d) . Furthermore, intratumoral injection of the MEK inhibitor selumetinib inhibited tumour growth (Fig. 6d,e) and reduced ERK1/2 phosphorylation, PKM2 expression (Fig. 6f) and lactate production in tumour tissue (Fig. 6g) . These results highlight the significance of ERKdependent nuclear translocation of PKM2 and PKM2-dependent gene transcription in the Warburg effect and brain tumour development.
To determine whether our findings have clinical relevance, we examined the activity of EGFR and ERK1/2 with PKM2 Ser 37 Note that some of the dots on the graphs represent more than one specimen (that is, some scores overlapped). (c) Schematic representation of the PKM2-dependent regulation of the Warburg effect. EGFR activation in human cancer cells induces PKM2 nuclear translocation, which is mediated by PKM2 phosphorylation by ERK, followed by PIN1-regulated cis -trans isomerization of PKM2 and subsequent binding to importin α5. Nuclear PKM2 is required for EGF-induced β-catenin transactivation and induction of c-Myc expression, which in turn and thereby upregulates the expression of glycolytic enzymes such as GLUT1, LDHA and also the PTB-dependent expression of PKM2. Thus, nuclear PKM2-dependent expression of these glycolytic enzymes promotes the Warburg effect.
phosphorylation in serial sections of 48 human primary GBM specimens by immunohistochemical analyses by using antibodies with validated specificities (Supplementary Fig. S7e ). As shown in Fig. 7a , the levels of EGFR and ERK1/2 activities correlated with the levels of PKM2 Ser 37 phosphorylation. Quantification of the staining showed that this correlation was statistically significant among different specimens (Fig. 7b: top panel, r = 0.77,p < 0.001; bottom panel, r = 0.78,p < 0.001). These results strongly suggest that EGFR-and ERK1/2-induced PKM2 Ser 37 phosphorylation occurs in human GBM.
DISCUSSION
The Warburg effect, which was first reported in 1924 (ref. 24) , is a widely observed feature in tumours. High aerobic glycolysis by malignant tumours is used clinically to diagnose and monitor treatment responses of cancers by imaging uptake of 2-18 F-deoxyglucose with positron emission tomography 1 . Despite its widespread appreciation and clinical application, the mechanisms underlying the Warburg effect remain largely unclear 1, 25 . Here, we demonstrate that nuclear translocation of PKM2 promotes the Warburg effect and reveal an important mechanism underlying this process: EGFR activation promotes aerobic glycolysis by means of a PKM2-dependent positive feedback loop supporting PKM2 expression as well as the expression of GLUT1 and LDHA. EGFR activation results in nuclear translocation of PKM2, which is mediated by the ERK1/2-dependent phosphorylation of PKM2 Ser 37 and consequently PIN1-catalysed cis-trans isomerization of PKM2 for binding to importin α5. Nuclear PKM2 regulates β-catenin transactivation-dependent MYC transcription and, subsequently, the expression of GLUT1, LDHA and PTB-mediated PKM2 expression. The upregulation of these rate-limiting glycolytic genes plays a critical role in the EGF-induced Warburg effect, featuring elevated glucose uptake and higher lactate production in the presence of oxygen, which leads to enhanced brain tumour development (Fig. 7c) . Moreover, PKM2 Ser 37 phosphorylation correlates with EGFR and ERK1/2 activity in human GBM, implying that PKM2 nuclear translocation might play a significant role in the progression of these tumours in humans.
The mechanisms underlying the inability of PKM1 to compensate for the loss of PKM2 in the Warburg effect and tumorigenesis were not well understood 8 . We demonstrate here that PKM1, which lacks both a docking domain and the NLS encoded by exon 10, did not bind activated ERK2 and was not phosphorylated at Ser 37. PKM1 remained in the cytosol after EGF treatment. Although PKM1 and PKM2 are both capable of converting phosphoenolpyruvate (PEP) to pyruvate, only PKM2 is able to translocate to the nucleus to conduct its unique nuclear functions. These functions include, but may not be limited to, transactivation of β-catenin phosphorylated at Tyr 333, histone H3 phosphorylation and subsequent transcription of its downstream genes, such as MYC and CCND1, and promotion of cell cycle progression 10, 14 and the Warburg effect. Given that c-Myc and cyclin D1 play instrumental roles in cell proliferation, survival and metabolism, our findings underscore the significant role of the metabolic and nonmetabolic functions of PKM2 in a very broad area of cellular activities. These findings also highlight the distinct functions of PKM2 relative to those of PKM1 in tumour development. Compared with the relatively well-studied cytosolic functions of PKM2, the illustrated nuclear functions of PKM2 in tumour development and its regulatory mechanisms for expression of glycolic enzymes and cyclin D1 provide important insights into PKM2-promoted tumour progression and targets for treating human cancer.
METHODS
Methods and any associated references are available in the online version of the paper. 
M E T H O D S
METHODS
Cells and cell culture conditions. U87, U87/EGFR and U251 GBM cells as well as 293T, PIN1 +/+ and PIN1 −/− cells were maintained in DMEM supplemented with 10% bovine calf serum (HyClone). These cell cultures were made quiescent by growing them to confluence and then replacing the medium with fresh medium containing 0.5% serum for 1 day. GSC11 human primary GBM cells were maintained in DMEM/F-12 50/50 supplemented with B27, EGF (10 ng ml −1 ) and basic fibroblast growth factor (10 ng ml −1 ). GSC11 cell cultures were made quiescent similarly, by growing them to confluence and then replacing the medium with fresh medium containing 0.5% serum for 1 day.
Transfection. Cells were plated at a density of 4 × 10 5 /60-mm dish 18 h prior to transfection. Transfection was carried out using HyFect reagents according to the vendor's instructions. Transfected cultures were selected with puromycin (5 µg ml −1 ), hygromycin (200 µg ml −1 ) or G418 (400 µg ml −1 ) for 10-14 days. At that time, antibiotic-resistant colonies were picked, pooled and expanded for further analysis under selective conditions.
Immunoprecipitation and immunoblotting analyses. Extraction of proteins
with a modified buffer from cultured cells was followed by immunoprecipitation and immunoblotting with corresponding antibodies, as described previously 26 .
DNA constructs and mutagenesis. PCR-amplified human importins α1, α3, α5
and α7 were cloned into pcDNA3.1/hygro (+) vector between BamHI and NotI. PCR-amplified human importins α4 and α6 were cloned into pcDNA3.1/hygro (+) vector between EcoRV and NotI. PCR-amplified human PKM2 was cloned into either pCold I vector (TaKaRa) or pcDNA3.1/hygro (+) vector between BamHI and XbaI. pcDNA 3.1/hygro (+)-PKM2 S37A, S37D, I428R/V430A, I429R/L431R, R399/400A and R443/445/447A, pcDNA 3.1/hygro (+)-rPKM2 and pBabe-PIN1 L60/61A and C113A were made using the QuikChange site-directed mutagenesis kit (Stratagene). pCDNA 3.1 rPKM2 contains non-sense mutations of C1170T, C1173T, T1174C and G1176T. pGIPZ control was generated with a control oligonucleotide (5 -CTTCTAACAC-CGGAGGTCTT-3 ). pGIPZ PKM2 shRNA was generated with 5 -CATCTACCACT-TGCAATTA-3 oligonucleotide targeting the transcript of the PKM2 exon 10. pGIPZ KPNA1 shRNA was generated with 5 -GGCCTTTGATCTTATTGAGCA-5 oligonucleotide.
Measurements of glucose consumption and lactate production. Cells were seeded in culture dishes, and the medium was changed after 6 h with no-serum DMEM. Cells were incubated for 12-16 h, and the culture medium was then collected for measurement of glucose and lactate concentrations. Glucose levels were determined using a glucose (GO) assay kit (Sigma). Glucose consumption was the difference in glucose concentration when compared with DMEM. Lactate levels were determined using a lactate assay kit (Eton Bioscience).
Purification of recombinant proteins. Wild-type and mutant His-PKM2, GST-PIN1 and GST-importin α5 proteins were expressed in bacteria and purified, as described previously 27 .
In vitro kinase assays. Kinase reactions were carried out as described previously 3 .
Luciferase reporter gene assay. Transcriptional activation of β-catenin in 293T cells was measured as described previously 28 .
In vitro isomerization assay. The isomerization rate was shown with the cispeptide content, which was determined by isomer-specific proteolysis. Cis-peptides were prepared by incubating the peptides with α-chymotrypsin at 0 • C for 2 min to completely hydrolyse the trans isomer at the 4-nitroanilide bond to obtain the pure cis-peptides. The pure cis-peptides were left to re-equilibrate. As the isomerization proceeded, aliquots were taken at the indicated time. Chymostatin was added to inactivate chymotrypsin. The absorbance of the released 4-nitroaniline was measured at 405 nm.
Immunofluorescence analysis. Cells were fixed and incubated with primary antibodies, Alexa Fluor dye-conjugated secondary antibodies and Hoechst 33342 according to standard protocols. Cells were examined using a deconvolution microscope (Zeiss) with a 63-Å oil immersion objective. Axio Vision software from Zeiss was used to deconvolute Z-series images.
Subcellular fractionation.
Nuclei, cytosol and cell membrane were isolated using a nuclear extract kit from Active Motif North America (Carlsbad) and the ProteoExtract subcellular proteome extraction kit from Calbiochem. Nuclear proteins (60 µg) and cytosolic proteins (14 µg) were used in immunoblotting analyses.
ChIP assay. ChIP was carried out using an Upstate Biotechnology kit. Chromatin prepared from cells (in a 10-cm dish) was used to determine total DNA input and for overnight incubation with the specific antibodies or with normal rabbit or mouse immunoglobulin G. The human MYC promoter-specific primers used in PCR were 5 -CAGCCCGAGACTGTTGC-3 (forward) and 5 -CAGAGCGTGGGATGTTAG-3 (reverse). Immunohistochemical analysis. Mouse tumour tissues were fixed and prepared for staining as previously described 10 . The specimens were stained with Mayer's haematoxylin and subsequently with eosin (Biogenex Laboratories). Afterwards, the slides were mounted using Universal Mount (Research Genetics).
Bioluminescence imaging with IVIS. Mice were anaesthetized with isoflurane inhalation, and were subsequently intraperitoneally injected with 100 µl of 7.5 mg ml −1 D-luciferin (Xenogen). Bioluminescence imaging with a CCD camera (IVIS, Xenogen) was initiated 10 min after injection with 2 min exposure time. Bioluminescence from the region of interest was defined manually. Background was defined using a region of interest from a mouse that was not given an intraperitoneal injection of D-luciferin. All bioluminescent data were collected and analysed using IVIS.
Intracranial injection. We intracranially injected 5×10 5 U87/EGFRvIII or GSC11 cells with or without RNAi-depleted PKM2 and reconstitution of rPKM2 or NATURE CELL BIOLOGY Materials. Rabbit polyclonal antibodies recognizing phospho-PKM2 ser 37, PKM2, EGFR, phospho-EGFR Tyr 1172 and c-Myc were obtained from Signalway Antibody. Polyclonal antibodies for GST, ERK, PCNA, MEK1, PTB and LDHA and monoclonal antibody for phospho-ERK1/2 (sc-7383, clone E-4; 1:1,000 dilution for immunoblotting) were purchased from Santa Cruz Biotechnology. EGF, rabbit polyclonal antibody for Flag (F7425; 1µg for immunoprecipitation), monoclonal secondary anti-rabbit IgG (R3155; native peroxidase reacts speci cally with non-reduced rabbit IgG and does not react with reduced rabbit IgG) and mouse monoclonal antibodies for Flat (F3165, clone M2; 1:5,000 dilution for immunoblotting), His (H1029, clone HIS-1; 1:2,000 dilution for immunoblotting) and tubulin (T9026, clone DM1A; 1:2,000 dilution for immunoblotting were purchased from Sigma. Hygromycin, puromycin, G418, LY290042, SU6656, SP600125 and U0126 were purchased from EMD Biosciences. Active ERK2 was obtained from Signalchem. Hoechst 33342 and Alexa Fluor 488 goat anti-rabbit antibody were from Molecular Probes. HyFect transfection reagents were from Denville Scienti c. GelCode Blue Stain Reagent was obtained from Pierce.
The tissue sections from para n-embedded human GBM specimens were stained with an antibody against phospho-EGFR Tyr 1172, phospho-PKM2 Ser 37 (Signalway Antibody) or phospho-ERK (Santa Cruz) or with nonspeci c immunoglobulin G as a negative control. We quantitatively scored the tissue sections according to the percentage of positive cells and the staining intensity, as previously de ned 10 . We assigned the following proportion scores: 0 if 0% of the tumour cells showed positive staining, 1 if 0-1%, 2 if 1-10%, 3 if 11-30%, 4 if 31-70% and 5 if 71-100%. We rated the intensity of staining on a scale of 0 to 3: 0 for negative, 1 for weak, 2 for moderate and 3 for strong. e proportion and intensity scores were combined to obtain a total score (range 0-8), as described previously 5 . Scores were compared with overall survival, de ned as the time from date of diagnosis to death or last known date of follow-up. All patients had received standard adjuvant radiotherapy a er surgery, which had been followed by treatment with an alkylating agent (temozolomide in the majority of cases). e use of human brain tumour specimens and the database was approved by the institutional review board at the MD Anderson Cancer Center. Cis-trans isomerization assays were performed by mixing synthesized phosphorylated oligopeptide of PKM2 containing the S37P motif with purified WT GST-PIN1 or GST-PIN1 L60/61A mutant. Data represent the means ± SD of three independent experiments. (e) The indicated cells expressing Flag-PKM2 were treated with or without EGF (100 ng/ml) for 6 h, and the nuclear fractions were prepared. Immunoblotting analyses were performed with the indicated antibodies. (f) U87/EGFR cells expressing a control shRNA or expressing HIF1a shRNA (left panel) were treated with or without EGF (100 ng/ml) for 6 h. The nuclear fractions were prepared (right panel). Immunoblotting analyses were performed with the indicated antibodies.
